Unlike marketing authorization for pharmaceuticals, mainly regulated at the European level, Pricing and Reimbursement decisions within the European Union are country-specific and operating under the Ministry of Health supervision. Based on each country regulation, variations do exist in Pricing and Reimbursement decision in pharmaceuticals.

Therefore, it is necessary that those who are involved in the development of innovative drugs are knowledgeable about:

• Current context of pricing and reimbursement decisions in the European Union
• Different approaches of pricing and reimbursement decisions across the European Union
• Evidence requirements for successful pricing and reimbursement strategy

CataloniaBio and Insights in life Sciences (ilS) co-organize this training course in order to provide detailed information about the complex Reimbursement Systems for Pharmaceuticals in the TOP 5 European countries (France, Germany, Italy, Spain and United Kingdom), as well as compare, and bring into contrast their key characteristics.

The training course is going to be delivered by Spanish top-notch representatives, professionals, and teachers from the areas of Market Access:

Dr. Pepi Hurtado, Partner in ilS

Dr. Pepi Hurtado has extensive experience in the pharmaceutical and biotechnology industry at global and national levels. She worked as senior consultant at IMS Health and as an independent consultant at her own company (DelScience). Prior to becoming a consultant, she had experience as a researcher both in academia and pharmaceutical industry. Additionally. Dr. Hurtado has a broad training in scientific fields, holds an MSc in Pharmacy (Universitat de Barcelona) and a Ph.D. in Pharmaceutical Technology (University of London).

Dr. Itziar Escudero, Partner in ilS

Dr. Itziar Escudero has extensive experience in entrepreneurship, business development and strategic consulting in the pharmaceutical, biotech and medical device industries, both at national and international level. She worked for international firms such as Ernst & Young and PwC. Dr. Escudero holds an M.B.A. degree from the University of California, a Ph.D. in Biochemistry and Molecular Biology from the Universitat de Barcelona, and a Masters in Chemical Sciences with a specialization in Biochemistry from Universidad Autónoma de Madrid.

Ms. Laura Guarga, Project Manager in ilS

Ms. Laura Guarga has experience in pharmaceutical and biotechnology industry at national and international level. She worked as analyst at IMS Health (HEOR department) and had previous experience in community and hospital pharmacy. She holds a MSc in Pharmacy, a Masters in Drug Dependence from the Universitat de Barcelona and a Postgrad in Business Management at Universitat Autònoma de Barcelona

Dr. Arantxa Catalan, Chief of Pharmacy Evaluation in Agency for Health Quality and Assessment of Catalonia (AQuAS)

Dr. Catalan is also responsible of the Innovation and Medicines support Program in AQUAS. Prior to her current role, she held various management positions in the Catalan Institute of Health (ICS) and was the Chairman of Spanish Society of Pharmacists and Primary Care (SEFAP). She is a Hospital Pharmacist, has a Ph.D. in Pharmacy from Universidad de Navarra and holds a Master degree in Health Economics and Pharmacoeconomics from Universitat Pompeu Fabra (UPF).